TRKA expression and NTRK1 gene copy number across solid tumours.

摘要: Aims Neurotrophic Tropomyosin Kinase Receptor 1 ( NTRK1 ) gene encodes for the protein Tropomyosin-related kinase A (TRKA). Deregulated activity of TRKA has been shown to have oncogenic potential. We present here results an immunohistochemical (IHC) observational cohort study expression together with copy number (GCN) assessment in various solid tumours. Methods Formalin-fixed, paraffin-embedded consecutive samples different tumour types were tested expression. Samples showing IHC staining at least 10% cells analysed by fluorescence situ hybridisation assess rearrangements and/or individual GCN gain. All patients underwent this molecular within phase I ALKA-001 clinical trial. Results 1043 and annotation histology was available 1023. Most colorectal adenocarcinoma (CRC) (n=550, 52.7%) lung (n=312, 29.9%). 24 (2.3%) biliary tract carcinoma (BTC). Overall, 17 (1.6%) characterised (four weak, eight moderate, five strong): 9/17 adenocarcinoma, 3/17 CRC, BTC, 1/17 thyroid cancer unknown primary. Of these, strong displayed rearrangement 15/17 gain FISH. No correlation found between intensity copies . Conclusions can be 1.6% tumours paralleled or mostly The prognostic translational therapeutic impact latter remains established.